Protara Therapeutics Secures $198M Cash Runway into 2028, Reports Positive Clinical Progress

summarizeSummary

Protara Therapeutics reported a strong cash position of $197.9 million, including proceeds from an $86.3 million public offering, extending its cash runway into 2028, alongside positive clinical trial updates and regulatory designations for its lead candidates.

check_boxKey Events

• Strong Cash Position and Runway

  The company reported $197.9 million in cash, cash equivalents, and marketable debt securities as of December 31, 2025, which is projected to fund operations into 2028.

• Successful Public Offering

  Protara Therapeutics completed an oversubscribed $86.3 million public offering in December 2025, significantly bolstering its capital reserves.

• Positive NMIBC Trial Data

  Updated interim results from the Phase 2 ADVANCED-2 trial for TARA-002 in non-muscle invasive bladder cancer (NMIBC) showed a 68% complete response rate at six months in BCG-Unresponsive patients.

• Breakthrough & Fast Track Designations for LMs

  TARA-002 received both Breakthrough Therapy and Fast Track designations from the FDA for the treatment of lymphatic malformations (LMs), with a regulatory update expected in 1H 2026.

auto_awesomeAnalysis

Protara Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a significantly strengthened balance sheet with $197.9 million in cash, cash equivalents, and marketable debt securities as of December 31, 2025. This includes proceeds from a successful $86.3 million public offering completed in December 2025, which is expected to fund operations into 2028. This substantial capital raise provides critical financial stability for the clinical-stage biotechnology company. The filing also provided positive updates on its pipeline, including encouraging interim data for TARA-002 in bladder cancer and key regulatory designations for TARA-002 in lymphatic malformations, further de-risking its development programs.